Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback on June 01, 2026 Agios Autoimmune thrombocytopenia Cevidoplenib Failure (biologic function) Hematological Disease Inhibitor Inosine Triphosphate ITP Oscotec Phase 2 Clinical Trials SYK +
Agios' Sickle Cell Trial Falls Short as Mitapivat Fails to Significantly Reduce Pain Crises on November 20, 2025 Agios Anemia, Sickle Cell Clinical Trials hemoglobin response mitapivat pain crises PYRUKYND Rise Up trial +
FDA Pushes Back Agios' Pyrukynd Thalassemia Decision to December on September 05, 2025 Agios decision delay Liver damage PDUFA PYRUKYND REMS Thalassemia United States Food and Drug Administration +
Leadership Changes at Agios and Moderna: Board Resignation and New Marketing Chief on February 17, 2025 Agios Board Resignation Changing Chief David Schenkein Drug Industry Leadership Mahery marketing officer Moderna +